MYX 0.90% $4.39 mayne pharma group limited

That's the initial consideration. After later reports from the...

  1. 550 Posts.
    That's the initial consideration. After later reports from the parent company showed that sales for FY17 would be $US700 to $US750, the purchase agreement let Hikma renegotiate the cash upfront down by $US550m... from I think the initial agreement of $1.1B.

    So final price for Roxanne was $2.1B, at operating margin of 35% like you quoted up there, that's EBIT of .35*700 = $US245m, or 8.6 P/EBIT.

    Maybe paid practically $AUD1B [when you include the transaction, working capital, technical transfer] for a portfolio with FY17 sales of $US237m. EBITDA margin at 50% [they reckon] put earnings at $US118.5.

    At current exchange rate, that's price of $US780m to $US118.5 or 6.58.

    So it's cheaper on that PE measure. Here's the BUT...

    Hikma's purchase only dilute its ownership b 16.7% compare to Mayne's issuing the equivalent of some 80% of existing shares.

    Hikma immediately become the top 6 generic company vs Mayne's top 25.

    Pipeline potentials of some US41b vs $US7b.

    Get the labs, the R&D team and continued shared interests from the seller.
 
watchlist Created with Sketch. Add MYX (ASX) to my watchlist
(20min delay)
Last
$4.39
Change
-0.040(0.90%)
Mkt cap ! $373.4M
Open High Low Value Volume
$4.44 $4.48 $4.22 $618.1K 142.5K

Buyers (Bids)

No. Vol. Price($)
1 693 $4.33
 

Sellers (Offers)

Price($) Vol. No.
$4.40 2133 2
View Market Depth
Last trade - 16.10pm 04/11/2024 (20 minute delay) ?
MYX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.